Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Asset Writedowns and Impairment (2024 - 2025)

TriSalus Life Sciences' Asset Writedowns and Impairment history spans 2 years, with the latest figure at $34000.0 for Q3 2025.

  • For Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to $34000.0; the TTM value through Sep 2025 reached $317000.0, changed N/A, while the annual FY2024 figure was $187000.0, N/A changed from the prior year.
  • Asset Writedowns and Impairment reached $34000.0 in Q3 2025 per TLSIW's latest filing, down from $57000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $187000.0 in Q4 2024 to a low of $34000.0 in Q3 2025.